Articles

Federated Learning (FL) is transforming healthcare AI by allowing models to learn from data stored in different hospitals and devices without moving or sharing sensitive patient information. Unlike traditional centralized AI, FL keeps data private and secure, complying with strict regulations. Originally developed by Google, FL supports secure collaboration, fairness among small and large providers, and stable, personalized AI even with diverse or limited data. It also makes AI models more explainable and trustworthy for clinicians. Overall, FL turns privacy challenges into strengths, enabling hospitals to jointly build powerful, ethical, and inclusive AI models while protecting patient data.
Why Federated Learning is the Next Big Thing in Healthcare AI   The use of Artificia…

Read on to explore how we’re setting a new standard in peptide delivery. This initiative is strategically designed to accelerate the drug discovery journey for small-molecule-focused biotech companies by providing peptides with speed, precision, and reliability.
Timely access to high-quality peptides is essential in drug discovery, especially for screening, structure-activity relationship (SAR) studies, and early-stage preclinical research. Any delay in peptide synthesis can slow down critical experiments, affect project timelines, and limit the ability to make rapid decisions in lead optimisation. Recognising the critical role of fast, reliable, and risk-free peptide delivery in accelerating the development of new therapies, launched the o2h Peptide Guarantee Programme, designed to deliver…

The MD-42 License, issued by India’s Central Licensing Authority, is mandatory for manufacturing Class C and D medical devices like stents and implants. To obtain it, manufacturers must have ISO 13485-compliant facilities, qualified staff, and follow GMP. The application involves submitting detailed documentation via the CDSCO SUGAM portal, paying fees, and passing inspections. Valid for 5 years, the MD-42 License ensures regulatory compliance, builds trust, and enables market access. Expert assistance can simplify the process and help avoid delays or rejections.
What is an MD-42 License? An MD-42 license is granted by the Central Licensing Authority (CLA) to manufacturers of Class C and D medical devices. This license ensures your products meet strict safety, quality, and performance stand…

Nicolas Wolikow is a French entrepreneur and co-founder and CEO of Cure51. A graduate of Sciences Po and HEC, he began his career in a ministerial cabinet (Quai d'Orsay) and then within major French groups (L'Oréal, Sodexo) in marketing and international development roles (opening subsidiaries in emerging countries).
1. Let’s start with the big picture — what inspired the founding of Cure51, and what core mission drives the company today? The original spark behind Cure51 came from a simple but powerful observation: some patients with very advanced cancer live far beyond expectations—and yet we rarely ask why. In most oncology R&D models, these exceptional survivors are statistical outliers, often excluded from clinical analysis. At Cure51, we decided to flip that thinking. What if these…

Innovation in pharmaceutical secondary packaging is so much more than a competitive advantage – in today’s market, it is a vital tool for supporting sustainability and securing optimal patient outcomes. As the industry faces mounting regulatory pressure, supply chain volatility, and shifting patient and societal expectations, utilising the latest innovations is now central to ensuring product integrity, regulatory compliance, and brand trust.
Why innovation matters now  The pharmaceutical sector is navigating a period of volatility and change. Regulatory frameworks are tightening worldwide, demanding more robust serialisation, anti-counterfeiting measures, and environmental accountability. At the same time, the push for sustainability, and the need for improved patient engagement are…

Discover how computer vision software development services are revolutionizing healthcare through AI diagnostics, patient monitoring, and workflow automation.
Introduction to Computer Vision in Healthcare Let’s face it—healthcare can be slow, expensive, and prone to human error. But what if a camera and some smart algorithms could help change that? That's where computer vision steps in. By mimicking the human eye and brain, computer vision enables machines to understand and interpret visual data. In healthcare, this technology is becoming a game-changer. From reading complex medical scans to monitoring patients around the clock, computer vision software development is redefining what's possible in modern medicine. As a computer vision software development company, we've seen firsthand how t…

The Medical Telepresence Robots Market is projected to grow from USD 66.2 million in 2023 to USD 322.1 million by 2032, at a CAGR of 19.3%. This growth is driven by the rise in telemedicine, healthcare professional shortages, aging populations, and the need for infection control. Key market trends include AI integration, 5G connectivity, and expanding use in hospitals, home care, and senior living. North America leads the market, with Asia-Pacific emerging as the fastest-growing region.
Medical Telepresence Robots Market Overview: Unlocking the Future of Remote Healthcare In an increasingly digital healthcare landscape, Medical Telepresence Robots are emerging as a game-changing solution to bridge gaps in care delivery, especially in underserved or geographically distant locations. Accordin…

As per the Ultomiris Drug Market analysis conducted by the CMI team, the ultomiris drug market is expected to record a CAGR of 31.52% from 2025 to 2034. In 2025, the market size was USD 5.47 Billion. By 2034, the valuation is anticipated to reach USD 64.12 Billion.
Reports DescriptionAccording to the analysis conducted by Custom Market Insights (CMI), the Ultomiris drug market is projected to grow at a compound annual growth rate (CAGR) of 31.52% from 2025 to 2034. In 2025, the market size was valued at USD 5.47 billion, and it is anticipated to reach approximately USD 64.12 billion by the year 2034. https://www.custommarketinsights.com/report/ultomiris-drug-market/ OverviewUltomiris competes with Soliris (eculizumab), but its extended dosing interval provides a clear clinical advantage. Th…

Big data is changing clinical research by helping doctors choose the right patients, understand results better, and speed up the process of finding new treatments. This makes medical studies faster and more accurate.
The way we study new medicines and treatments is changing quickly. One of the biggest reasons for this change is the use of artificial intelligence (AI) and big data in clinical research. These technologies are helping doctors and researchers collect, understand and use medical information faster and better than before. During a good clinical research course students often learn how new tools like AI and big data are now part of modern research work. In the past, clinical research relied mostly on paperwork, manual data entry and slow methods to find answers. Today, computers c…

Healthcare app development services are reshaping the industry by making care more accessible, efficient, and secure. With telemedicine, remote monitoring, and wellness apps, providers can improve patient engagement and operational efficiency. Choosing the right healthcare app development company ensures innovative, compliant, and scalable digital health solutions.
The healthcare industry is at the forefront of a digital revolution that is reshaping how care is delivered, accessed, and experienced. With the rise of smartphones, wearable devices, and remote healthcare solutions, patients no longer view medical care as something limited to hospitals or clinics. Today, healthcare is mobile, intelligent, and always accessible — and at the center of this transformation lie cutting-edge healthc…

Superficial thrombophlebitis is a common vein condition marked by pain, redness, swelling, and inflammation due to a clot in a superficial vein, usually in the legs or arms. While not as serious as deep vein thrombosis, it still needs timely care. This blog covers everything from causes and symptoms to effective treatment using Thrombophob Gel, a doctor-trusted topical medicine containing heparin that promotes blood flow and reduces clotting. It clarifies confusion around terms like thermophob or thromboph, emphasizing that Thrombophob Gel is the correct and reliable product for targeted relief. With home care tips like elevation, warm compresses, and compression stockings, you can recover comfortably. Learn how to manage vein pain and inflammation naturally and effectively. Buy Thrombophob Gel now at OnlineGenericMedicine.

HPAPIs: Small but Mighty...in Big Pharma Development: Today’s drug developers have never faced smaller and more potent therapeutics than those emerging in the HPAPI space. Yet these molecules pack a punch: while they are delivered in microgram or milligram doses, the requirements for safety, compliance and technical know-how are huge. As pharma companies look for nimble and expert partners in their supply chains, CDMOs active in HPAPIs and oncology are moving from specialty to mainstream in this field.
The High Potency Active Pharmaceutical Ingredient (HPAPI) contract manufacturing market is red hot right now. Shifts to targeted and more personalized medicines (especially oncology, hormonal, and autoimmune drugs), coupled with the continued need for high-volume API supply are opening the…

The CDMOs behind active pharmaceutical ingredients are no longer silent suppliers—they are strategic partners shaping the future of medicine. As therapies get more complex and the pharmaceutical supply chain becomes more decentralized and transparent, the API CDMO market is ready to deliver—faster, safer, and smarter.
The Active Pharmaceutical Ingredient (API) CDMO market has entered the limelight as global pharma pipelines continue to balloon, while speed to market, safety and scalability requirements also ramp up. The API CDMO market size is expected to rise at a steady pace through 2030. Driving factors include global outsourcing trends, supply chain decentralization, and a host of industry reforms to improve quality, transparency, efficiency, and resilience. Active pharmaceutical ingred…

IgA nephropathy (also known as Berger’s disease) is a kidney disorder caused by the buildup of immunoglobulin A (IgA) deposits in the kidneys, leading to inflammation and potential damage to kidney structures.
What is IgA nephropathy? IgA nephropathy (also known as Berger’s disease) is a kidney disorder caused by the buildup of immunoglobulin A (IgA) deposits in the kidneys, leading to inflammation and potential damage to kidney structures. The global IgA nephropathy market is currently in the growth stage of its lifecycle, driven by increasing awareness, improved diagnostic capabilities, and advancements in renal treatment options. What kind of new strategies are being adopted by the existing market players to strengthen their market position in the industry? Existing market players in th…

The South Korea flow cytometry market was valued at $74.55 million in 2023 and is projected to reach $244.5 million by 2033, growing at a robust CAGR of 12.89% during the forecast period (2024–2033). Investments in flow cytometry in the country saw a significant year-on-year increase of 23.23% from $431.3 million in 2020 to $531.5 million in 2021. This upward trend reflects the growing importance of this technology across clinical, research, and industrial domains.
What is the flow cytometry market? Flow cytometry is a technique employed in laboratories to analyze the physical and chemical properties of cells or particles as they flow in a fluid stream through a laser. This market includes flow cytometers, which are the primary instruments used for cell analysis and sorting, along with reag…

As awareness grows and technology advances, Guillain-Barré Syndrome is becoming less of a mystery—and more of a manageable, diagnosable condition. The future of GBS care starts with faster answers.
While it is not a common condition, Guillain-Barré Syndrome (GBS) is garnering increased interest from the broader medical diagnostics industry as new cases are reported worldwide each year and linked to a range of triggers including infections, immunizations, or idiopathic origins. Early detection followed by appropriate care and treatment is a key need in GBS, which can lead to paralysis and other serious complications if left untreated. The global Guillain-Barré Syndrome diagnostics market is expected to show steady growth during the forecast period (2024-2030) with several factors such as gr…

Explore what a Lab Technician does, where they work, essential skills and qualifications, and how to start your career in laboratory technology. Perfect for jobseekers considering this dynamic and vital role.
Introduction If you’re detail-oriented and enjoy working with scientific equipment, a career as a Lab Technician could be the perfect fit for you. Lab Technicians are vital to the smooth running of laboratories in various industries, from healthcare to environmental science. In this article, you’ll learn what a Lab Technician does, where they work, the skills and qualifications required, and how you can start your career in this rewarding field. What is a Lab Technician? A Lab Technician is a professional who performs routine technical tasks and experiments in a laboratory setting. As…

The announcement of a Life Science Strategy from the European Commission [2 July] includes action to address long-standing issues that have been hampering the region’s competitiveness and preventing European patients access the latest advances in treatment. The Strategy represents a very welcome step-forward for life science companies operating in Europe.
Brussels, Thursday 3 July, 2025 The announcement of a Life Science Strategy from the European Commission [2 July] includes action to address long-standing issues that have been hampering the region’s competitiveness and preventing European patients access the latest advances in treatment. The Strategy represents a very welcome step-forward for life science companies operating in Europe. The focus on making it easier to conduct clinical tri…

"The Residence" will bring together psychiatric expertise, psychological care, holistic and complimentary therapies alongside cutting-edge technology - and, set in a prestigious London location, close to the stunning and serene green space of Richmond Park, a leading addiction expert has already hailed the new service as "a space of safety and hope, where people can focus entirely on their wellbeing, free from outside pressure”
Priory - the UK’s largest independent provider of mental health, addiction and adult social care services - is set to unveil The Residence – a ground-breaking new recovery “experience” set to redefine privacy and clinical excellence in mental health and addiction care. Located in a private wing of the prestigious Priory Hospital Roehampton, South-West London, The Res…

Stefan Oelrich, President of Bayer’s Pharmaceuticals Division has been elected as the new President of the European Federation of Pharmaceutical Industries and Associations (EFPIA) with Teresa Graham, CEO of Roche Pharmaceuticals and Carlos Gallardo, Chairman and CEO of Almirall as first and second Vice Presidents.
Brussels, 30 June Stefan Oelrich, President of Bayer’s Pharmaceuticals Division has been elected as the new President of the European Federation of Pharmaceutical Industries and Associations (EFPIA) with Teresa Graham, CEO of Roche Pharmaceuticals and Carlos Gallardo, Chairman and CEO of Almirall as first and second Vice Presidents. The new team told a press conference in Brussels that a rapidly changing geopolitical environment is reshaping the life sciences playing field – and…